Search - tctmd.com

Displaying 301 - 320 of 783

Sort: Relevancy | Date

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

November 18, 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

November 16, 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

News Conference News AHA 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

November 05, 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

October 25, 2019

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

News Conference News TCT 2019

NCSI Strategy for Acute MI Cardiogenic Shock Reaps Better Survival

October 10, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

News Conference News TCT 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

October 01, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

News Conference News TCT 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Yael L. Maxwell

September 29, 2019

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

September 28, 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.